A5314: Effect of LDMTX on Inflammation in HIV-infected Individuals

Study Location:

Baltimore

Topic:

HIVCardiovascular Disease and HIV

Clinicaltrials.gov Link:

https://clinicaltrials.gov/ct2/show/NCT01949116?term=a5314&rank=2

IRB#:

NA_00088694

Coordinator:

Ilene Wiggins, RN

Enrollment:

Closed

Trial Period:

Completed

A5314 is a phase II randomized, double-blind, placebo-controlled 36-week trial that will examine the safety and efficacy of LDMTX on endothelial function and inflammation in virologically suppressed HIV-infected participants.

HIV-infected men and women ≥40 years old, who have been virologically suppressed on continuous antiretroviral therapy for at least 24 weeks; who have a CD4+ T-cell count ≥400 cells/mm3; and who have documented CVD or who are at increased CVD risk.

410-955-2898

Categories

Location
Topic

Clinical Trials

A5308: A Prospective, Single-Arm, Open-Label Study to...

This study is being done with people who are infected with HIV, but do not show any signs of having HIV. They are also feeling...

Read More

HPTN 069: A Phase II Randomized, Double-Blind, Study of the...

HPTN 069 is a phase II, four-arm, multisite, randomized, double-blinded trial. To assess the safety and tolerability of four...

Read More

P1078: A Phase IV Randomized Double-Blind Placebo-Controlled...

P1078 is a Phase IV, randomized, double-blind, placebo-controlled study of HIV-infected pregnant women and the infants born to...

Read More

A5288: MULTIOCTAVE, Management Using the Latest Technologies...

The study is being done to: test a strategy of using a resistance test to choose anti-HIV drugs. Resistance tests look at the...

Read More

A5324: A Randomized, Double-Blinded, Placebo-Controlled...

ACTG A5324 is a phase IV randomized, double-blinded, placebo-controlled study to assess the efficacy of adding Maraviroc (MVC)...

Read More